Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07013201 · ClinicalTrials.gov registry record · Phase 2
A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis
A Phase 2 study of Palmoplantar Pustulosis, sponsored by LEO Pharma.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 135
- Enrollment target
- 20
- Study locations
NCT07013201 is a Phase 2 study of Palmoplantar Pustulosis that is actively recruiting participants, run by LEO Pharma. The registered enrollment target is 135 participants. The trial reports 20 study locations across 13 states.
The verdict
NCT07013201, a Phase 2 study of Palmoplantar Pustulosis, is actively recruiting participants, sponsored by LEO Pharma.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 135 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main objective of the study is to evaluate the efficacy of twice daily applications of delgocitinib cream 20 mg/g compared with cream vehicle in the treatment of adult participants with mild to severe palmoplantar pustulosis (PPP). Total study duration for each participants will be approximately 18 weeks, for an approximate total of 9 visits.
Conditions Studied
Interventions
- DRUG Delgocitinib cream
- DRUG Vehicle cream
Study Locations (20)
Other
- LEO Pharma Investigational Site - Bad Bentheim
- LEO Pharma Investigational Site - Dresden
- LEO Pharma Investigational Site - Göttingen
- LEO Pharma Investigational Site - Kiel
- LEO Pharma Investigational Site - Lübeck
Ontario
- LEO Pharma Investigational Site - Hamilton
- LEO Pharma Investigational Site - Hamilton
- LEO Pharma Investigational Site - Markham
- LEO Pharma Investigational Site - Waterloo
California
- LEO Pharma Investigational Site - Fountain Valley
Georgia
- LEO Pharma Investigational Site - Douglasville
Michigan
- LEO Pharma Investigational Site - West Bloomfield
New York
- LEO Pharma Investigational Site - Elmhurst
Ohio
- LEO Pharma Investigation Site - Mayfield Heights
Oregon
- LEO Pharma Investigational Site - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2025-09-11 |
| Est. Completion | 2026-12-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07013201
The ClinicalTrials.gov registry entry for NCT07013201 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LEO Pharma, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Palmoplantar Pustulosis appearing as the primary indexed condition, and to 2 interventions - of which Delgocitinib cream is the first listed.
NCT07013201 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, Ontario, California.
Frequently Asked Questions
What is clinical trial NCT07013201 about?
NCT07013201 is a clinical study titled "A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis". The main objective of the study is to evaluate the efficacy of twice daily applications of delgocitinib cream 20 mg/g compared with cream vehicle in the treatment of adult participants with mild to severe palmoplantar pustulosis (PPP). Total study duration for each participants will be approximately...
What is the current status of trial NCT07013201?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 135 participants. The study started on 2025-09-11. Estimated completion is 2026-12-14.
What conditions does trial NCT07013201 study?
This clinical trial studies the following conditions: Palmoplantar Pustulosis.
What interventions are being tested in trial NCT07013201?
The interventions under investigation include: Delgocitinib cream (DRUG), Vehicle cream (DRUG).
Who is sponsoring clinical trial NCT07013201?
This trial is sponsored by LEO Pharma, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07013201 being conducted?
This trial has 20 study locations across California, Georgia, Michigan, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Palmoplantar Pustulosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.